Mounting An Attack On Lupus

June 02, 1997

Treatment options for systemic lupus erythematosus, an autoimmune disorder in which the immune system goes awry and attacks healthy tissues, may be expanded thanks to research conducted by Prof. Edna Mozes and colleagues of the Weizmann Institute's Immunology Department.

In a study reported in the Proceedings of the National Academy of Sciences (April 29, 1997, Vol. 94), Mozes's team synthesized two protein fragments that effectively immunized mice against lupus. The protein fragments were designed to mimic sections of the abnormal antibodies produced in lupus. Although their precise mechanism has not been fully clarified, studies indicate that they prevent the initiation of the autoimmune response. Where the disease already exists, preliminary results in mice suggest that the new compounds may also cure lupus and therefore serve as a basis for developing new treatments for humans.

Systemic lupus erythematosus strikes mostly women between the ages of 20 to 40 and affects many parts of the body, including joints, kidneys and skin. The cause of the disorder is unknown, and it is presently treated with general immune system- suppressing drugs that cause many unwanted side effects.

The new findings may lead to a more focused treatment that would selectively block the abnormal immune response and cause fewer side effects.

In a related study, Mozes and her team provided a scientific basis for studies suggesting that the drug methotrexate - generally prescribed to treat rheumatoid arthritis and some cancers - also has a beneficial effect on lupus. Using mice with an experimental lupus-like disease, the scientists demonstrated that methotrexate, which is known for its anti-inflammatory effects, reduces production of inflammatory molecules characteristic of the disease. This finding is reported in the Journal of Rheumatology (June 1997, Vol. 24, No. 6).

* Prof. Edna Mozes holds the Heinrich G. Ritzel Chair of Immunology. Her study reported in PNAS is now supported by Teva Pharmaceutical Industries, Ltd. The study that appeared in the Journal of Rheumatology was supported in part by the U.S.-Israel Binational Foundation and by the Crown Endowment Fund for Immunological Research.

The Weizmann Institute of Science is a major center of scientific research and graduate study located in Rehovot, Israel This publication, as well as other information on the Weizmann Institute, is posted on the World Wide Web at http://www.weizmann.ac.il, and news releases are also available at http://www.eurekalert.org
-end-


American Committee for the Weizmann Institute of Science

Related Lupus Articles from Brightsurf:

Systemic lupus erythematosus (SLE)
If renal remission is achieved therapeutically in cases of lupus nephritis (LN), the 10-year survival rate increases significantly.

Race-specific lupus nephritis biomarkers
A University of Houston biomedical researcher has discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

Lupus patients who take their medications lower their diabetes risk
Patients with lupus who take their medications as prescribed have much lower odds of developing type 2 diabetes, a common complication of the disease, finds a new study from the University of British Columbia.

Nearly 1 in 3 patients with lupus use prescription opioids for pain
A new study finds nearly one in three adults with lupus use prescription opioids to manage pain, despite a lack of evidence that opioids are effective for reducing pain from rheumatic diseases.

Developing therapeutic strategies for pregnant women with lupus
A highly gender-biased disease, lupus afflicts females some nine times more than males.

Lupus antibody target identified
Researchers have identified a specific target of antibodies that are implicated in the neuropsychiatric symptoms of lupus, according to human research published in JNeurosci.

B cells off rails early in lupus
Emory scientists could discern that in people with SLE, signals driving expansion and activation are present at an earlier stage of B cell differentiation than previously appreciated.

Can adverse childhood experiences worsen lupus symptoms?
Adverse childhood experiences (ACEs) encompass traumas such as abuse, neglect, and household challenges.

Unlocking the female bias in lupus
The majority of lupus patients are female, and new findings from the University of Pennsylvania shed light on why.

How a single faulty gene can lead to lupus
IBS-AIM (Academy of Immunology and Microbiology) research team at Pohang University of Science and Technology (POSTECH) in South Korea has discovered the role of a key gene involved in the autoimmune disease systemic lupus erythematosus (SLE) or lupus for short.

Read More: Lupus News and Lupus Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.